Effect of Romiplostim in Patients (pts) with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Azacytidine Kantarjian, H., Giles, F., Greenberg, P., Paquette, R., Wang, E., Gabrilove, J., Garcia-Mancro, G., Gray, J., Hu, K., Franklin, J. AMER SOC HEMATOLOGY. 2008: 89–90

View details for Web of Science ID 000262104700225